18:35

CALQUENCE® (acalabrutinib) ACE-CL-001 (ibrutinib-intolerant cohort) – Dr Raval, MD

14:09

CALQUENCE® (acalabrutinib) Safety Data – Dr Levy, MD

27:13

Dr Daniel Landau Presents CALQUENCE Long-Term and Pooled Cardiovascular Safety Data for CLL/SLL

19:00

CALQUENCE® (acalabrutinib) ELEVATE-RR and ASCEND Data – Dr Ma, MD

16:42

CALQUENCE® (acalabrutinib) Patient Management & Adherence – Bradley, NP

12:20

CALQUENCE® (acalabrutinib) Perspectives: Dr Alexey Danilov, MD, PhD

22:04

CALQUENCE® (acalabrutinib) ELEVATE-TN, Including 6-Year Median Follow-Up Data – Dr O’ Brien, MD

8:23

Sharon's Treatment Story